Responses to subsequent therapy following KI discontinuation
| . | Alternate KI combined . | Ibr → Idela . | Idela → Ibr . | BCL2-I . | CIT . | Mo anti-CD20 . |
|---|---|---|---|---|---|---|
| Number | 38 | 16 | 22 | 13 | 12 | 11 |
| ORR | 50% | 28% | 64% | 76% | 25% | 36% |
| CR | 0% | 0% | 0% | 7% | 17% | 9% |
| PR | 50% | 28% | 64% | 69% | 8% | 27% |
| SD | 30% | 45% | 23% | 16% | 33% | 45% |
| PD | 20% | 27% | 13% | 8% | 42% | 19% |
| . | Alternate KI combined . | Ibr → Idela . | Idela → Ibr . | BCL2-I . | CIT . | Mo anti-CD20 . |
|---|---|---|---|---|---|---|
| Number | 38 | 16 | 22 | 13 | 12 | 11 |
| ORR | 50% | 28% | 64% | 76% | 25% | 36% |
| CR | 0% | 0% | 0% | 7% | 17% | 9% |
| PR | 50% | 28% | 64% | 69% | 8% | 27% |
| SD | 30% | 45% | 23% | 16% | 33% | 45% |
| PD | 20% | 27% | 13% | 8% | 42% | 19% |
.